GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dermapharm Holding SE (STU:DMP) » Definitions » 3-Year EBITDA Growth Rate

Dermapharm Holding SE (STU:DMP) 3-Year EBITDA Growth Rate : 13.00% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Dermapharm Holding SE 3-Year EBITDA Growth Rate?

Dermapharm Holding SE's EBITDA per Share for the three months ended in Mar. 2024 was €1.84.

During the past 12 months, Dermapharm Holding SE's average EBITDA Per Share Growth Rate was -25.00% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 13.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 18.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Dermapharm Holding SE was 36.10% per year. The lowest was 13.00% per year. And the median was 16.90% per year.


Competitive Comparison of Dermapharm Holding SE's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermapharm Holding SE's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Dermapharm Holding SE's 3-Year EBITDA Growth Rate falls into.



Dermapharm Holding SE 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Dermapharm Holding SE  (STU:DMP) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Dermapharm Holding SE 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Dermapharm Holding SE's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermapharm Holding SE (STU:DMP) Business Description

Traded in Other Exchanges
Address
Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs and natural remedies. Its portfolio of products includes cosmetics, nutritional supplements and diet and medical devices. Business operating segments include Branded pharmaceuticals and other healthcare products which drive key revenue, Herbal extracts and Parallel import business. Branded pharmaceuticals and other healthcare products focus on the development, manufacturing and marketing of branded pharmaceuticals and other healthcare products. Herbal extracts include the manufacturing of phytopharmaceuticals, nutraceuticals and cosmetics products. Parallel import brands business operates under the AxiCorp brand.

Dermapharm Holding SE (STU:DMP) Headlines

No Headlines